Johnson & Johnson (JNJ) Stock Reaches Record Peak at $275.48

Key Highlights

• Stock peaked at $275.48, elevating market capitalization to $661 billion
• Yearly performance shows 53% appreciation, delivering 56.29% total return
• Second quarter revenue increased 6.6% reaching $25.31 billion; adjusted EPS at $2.90
• Company elevated 2026 revenue forecast to approximately $101.1 billion
• Wall Street analysts upgraded price targets, including Guggenheim’s $287 projection

On Tuesday, August 19, Johnson & Johnson reached an unprecedented peak of $275.48 per share, elevating its total market capitalization to $661 billion. The healthcare behemoth has delivered impressive returns, climbing 53% throughout the preceding twelve months.

Johnson & Johnson, JNJ

This milestone comes on the heels of impressive second-quarter performance. Revenue for Q2 expanded 6.6% year-over-year to reach $25.31 billion, while adjusted earnings registered at $2.90 per share. These figures exceeded Wall Street projections, prompting leadership to increase their 2026 financial guidance.

JNJ has updated its full-year 2026 projections, now anticipating approximately $101.1 billion in revenue with adjusted earnings per share at $11.68 (midpoint). This positions the company on the verge of achieving $100 billion in annual sales—a threshold reached by only a handful of healthcare corporations.

The recent surge benefited from a broader market rotation. With the Nasdaq experiencing downward pressure on Tuesday, capital flowed toward defensive positions. JNJ emerged as a primary beneficiary, advancing approximately 3% to $270.19 before establishing new records the subsequent trading day.

TREMFYA delivered revenue approximately $400 million beyond forecasts. Meanwhile, CAPLYTA and SPRAVATO similarly exceeded expectations, providing additional momentum for the analyst upgrades that emerged post-earnings.

Wall Street Raises Price Expectations

Guggenheim elevated its price objective to $287 from $270 while maintaining its Buy recommendation. The adjustment followed a site visit with senior leadership that informed their revised outlook.

Raymond James increased its target to $280 from $265. The firm’s analysis incorporated the recent FDA clearance for J&J’s Ottava robotic surgical system and its initial market rollout.

Freedom Capital made the most significant move, upgrading from Hold to Buy with a $280 price target. The firm emphasized second-quarter results that surpassed both consensus estimates and their internal projections.

JNJ boasts an impressive 55-year streak of consecutive dividend increases. This remarkable consistency continues to attract income-oriented investors, even as shares trade at elevated multiples.

Current Valuation Raises Eyebrows

The shares are trading at premium levels. JNJ currently commands a price-to-earnings multiple of 31.37. InvestingPro identifies the stock as overvalued compared to its Fair Value calculation.

According to the GF Value analysis, JNJ’s intrinsic fair value stands at $192.38, indicating current prices are approximately 41% above that benchmark. The market appears to be pricing in robust execution across its pharmaceutical pipeline and medical device operations.

In related healthcare sector news, Piper Sandler maintained its attention on Medtronic with a Neutral stance and $85 price objective. A survey involving 26 physicians indicated expectations for Medtronic to maintain leadership in PFA catheters and mapping technology through 2028.

As of August 19, JNJ shares were changing hands at $275.48, marking an all-time record for the stock.

The post Johnson & Johnson (JNJ) Stock Reaches Record Peak at $275.48 appeared first on Blockonomi.